Sachse-Seeboth C, Pfeil J, Sehrt D, Meineke I, Tzvetkov M, Bruns E, Poser W, Vormfelde S V, Brockmöller J
Department of Clinical Pharmacology, University Medicine, Göttingen, Germany.
Clin Pharmacol Ther. 2009 Mar;85(3):273-6. doi: 10.1038/clpt.2008.213. Epub 2008 Nov 12.
The impact of the CYP2C9 polymorphism on the pharmacokinetics of orally administered 9-tetrahydrocannabinol (THC) was studied in 43 healthy volunteers. THC pharmacokinetics did not differ by CYP2C92 allele status. However, the median area under the curve of THC was threefold higher and that of 11-nor-9-carboxy-9-tetrahydrocannabinol was 70% lower in CYP2C93/3 homozygotes than in CYP2C91/1 homozygotes. CYP2C93 carriers also showed a trend toward increased sedation following administration of THC. Therefore, the CYP2C9*3 variant may influence both the therapeutic and adverse effects of THC.
在43名健康志愿者中研究了CYP2C9基因多态性对口服9-四氢大麻酚（THC）药代动力学的影响。THC的药代动力学在CYP2C92等位基因状态方面并无差异。然而，与CYP2C91/1纯合子相比，CYP2C93/3纯合子中THC的曲线下面积中位数高出三倍，而11-去甲-9-羧基-9-四氢大麻酚的曲线下面积中位数则低70%。CYP2C93携带者在服用THC后也呈现出镇静作用增强的趋势。因此，CYP2C9*3变体可能会影响THC的治疗效果和不良反应。
